Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Articles|April 24, 2020
COVID-19: What Lies Ahead in Mental Health?
Author(s)Michelle Riba, MD, MS, DFAPA, FAPM
Michelle Riba, MD, shares her thoughts on the days ahead.
Advertisement
Patients with depression, anxiety, and other mental health problems are going to need us more ever in the days ahead. Dr Riba is Professor and Associate Chair, University of Michigan Department of Psychiatry; Associate Director, University of Michigan Comprehensive Depression Center; and Deputy Editor in Chief Emeritus, Psychiatric Times. University of Michigan Department of Psychiatry has an excellent resources page on its website:
Advertisement
Related to this article
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Should Postpartum Psychosis Be Included in the DSM?
4
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
5